Keywords: genentech, advises, shareholders, reject, roche, per, share

Genentech advises shareholders to reject Roche's $86.50 per share bid; growing hostility

Article | 02 March 2009

Print This

US biotechnology giant Genentech has advised its shareholders to reject the $86.50 per share offer made by Swiss drug major Roche.

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in